President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA breakthrough Device Designation, and what Imagion Biosystems expects to achieve in 2020.
10 Things to Know About MagSense®, Part 1: Why the Imaging Market Needs MagSense
October 22, 2026
Bringing molecular specificity to MRI could change the way cancer is diagnosed. We’re proud of the first-of-its-kind technology behind MagSense®, but breakthrough technology alone does